TY - JOUR
T1 - Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews
T2 - Proactive recruitment compared with self-referral
AU - Lieberman, Sari
AU - Tomer, Ariela
AU - Ben-Chetrit, Avi
AU - Olsha, Oded
AU - Strano, Shalom
AU - Beeri, Rachel
AU - Koka, Sivan
AU - Fridman, Hila
AU - Djemal, Karen
AU - Glick, Itzhak
AU - Zalut, Todd
AU - Segev, Shlomo
AU - Sklair, Miri
AU - Kaufman, Bella
AU - Lahad, Amnon
AU - Raz, Aviad
AU - Levy-Lahad, Ephrat
N1 - Funding Information:
This study was supported by a grant from the Breast Cancer Research Foundation (NY) (to E.L.L.).
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Purpose:Population screening of three common BRCA1/BRCA2 mutations in Ashkenazi Jews (AJ) apparently fulfills screening criteria. We compared streamlined BRCA screening via self-referral with proactive recruitment in medical settings.Methods:Unaffected AJ, age ≥25 years without known familial mutations, were either self-referred or recruiter-enrolled. Before testing, participants received written information and self-reported family history (FH). After testing, both non-carriers with significant FH and carriers received in-person genetic counseling. Psychosocial questionnaires were self-Administered 1 week and 6 months after enrollment.Results:Of 1,771 participants, 58% were recruiter-enrolled and 42% were self-referred. Screening uptake was 67%. Recruited enrollees were older (mean age 54 vs. 48, P < 0.001) and had less suggestive FH (23 vs. 33%, P < 0.001). Of 32 (1.8%) carriers identified, 40% had no significant FH. Post-Test counseling compliance was 100% for carriers and 89% for non-carrier women with FH. All groups expressed high satisfaction (>90%). At 6 months, carriers had significantly increased distress and anxiety, greater knowledge, and similar satisfaction; 90% of participants would recommend general AJ BRCA screening.Conclusion:Streamlined BRCA screening results in high uptake, very high satisfaction, and no excess psychosocial harm. Proactive recruitment captured older women less selected for FH. Further research is necessary to target younger women and assess other populations.Genet Med advance online publication 08 December 2016.
AB - Purpose:Population screening of three common BRCA1/BRCA2 mutations in Ashkenazi Jews (AJ) apparently fulfills screening criteria. We compared streamlined BRCA screening via self-referral with proactive recruitment in medical settings.Methods:Unaffected AJ, age ≥25 years without known familial mutations, were either self-referred or recruiter-enrolled. Before testing, participants received written information and self-reported family history (FH). After testing, both non-carriers with significant FH and carriers received in-person genetic counseling. Psychosocial questionnaires were self-Administered 1 week and 6 months after enrollment.Results:Of 1,771 participants, 58% were recruiter-enrolled and 42% were self-referred. Screening uptake was 67%. Recruited enrollees were older (mean age 54 vs. 48, P < 0.001) and had less suggestive FH (23 vs. 33%, P < 0.001). Of 32 (1.8%) carriers identified, 40% had no significant FH. Post-Test counseling compliance was 100% for carriers and 89% for non-carrier women with FH. All groups expressed high satisfaction (>90%). At 6 months, carriers had significantly increased distress and anxiety, greater knowledge, and similar satisfaction; 90% of participants would recommend general AJ BRCA screening.Conclusion:Streamlined BRCA screening results in high uptake, very high satisfaction, and no excess psychosocial harm. Proactive recruitment captured older women less selected for FH. Further research is necessary to target younger women and assess other populations.Genet Med advance online publication 08 December 2016.
KW - Ashkenazi Jewish
KW - BRCA1
KW - BRCA2
KW - hereditary breast and ovarian cancer
KW - population screening
UR - http://www.scopus.com/inward/record.url?scp=85024109450&partnerID=8YFLogxK
U2 - 10.1038/gim.2016.182
DO - 10.1038/gim.2016.182
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 27929526
AN - SCOPUS:85024109450
SN - 1098-3600
VL - 19
SP - 754
EP - 762
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 7
ER -